Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program-Reference-Cited by-同舟云学术

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Published:2019-04-03 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Verzoni Elena, ,Cartenì Giacomo,Cortesi Enrico,Giannarelli Diana,De Giglio Andrea,Sabbatini Roberto,Buti Sebastiano,Rossetti Sabrina,Cognetti Francesco,Rastelli Francesca,Sobrero Alberto,Turci Daniele,Sternberg Cora N.,Porta Camillo,Cappuzzo Federico,Tortora Giampaolo,Tassinari Davide,Panni Stefano,Pazzola Antonio,Surico Gianmarco,Raimondi Alessandra,De Giorgi Ugo,Procopio Giuseppe

Funder

Bristol-Myers Squibb

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0579-z.pdf

Reference29 articles.

1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

2. Farolfi A, Schepisi G, Conteduca V, Burgio SL, Lolli C, De Giorgi U. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. Expert Opin Drug Metab Toxicol. 2016;12(9):1089–96.

3. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.

4. Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for Nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017;72(6):962–71.

5. Administration USFD, FDA Expands Use of Immunotherapeutic to kidney cancer. http://blog.aacr.org/fda-approval-nivolumab-kidney-cancer/ 2015.

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis;Cancer Treatment Reviews;2024-09

4. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors;Japanese Journal of Clinical Oncology;2024-05-20

5. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología;2024-04